Related Experiment Video
Updated: Mar 21, 2026

04:13
Using a Real-Time Locating System to Measure Walking Activity Associated with Wandering Behaviors Among Institutionalized Older Adults
Published on: February 8, 2019
7.3K
Ambulatory Activity Components Deteriorate Differently across Neurodegenerative Diseases: A Cross-Sectional
Jochen Klenk1, Karin Srulijes, Cornelia Schatton
1Department of Clinical Gerontology, Robert Bosch Hospital, Stuttgart, Germany.
Neuro-Degenerative Diseases
|May 21, 2016
Summary
Reduced walking in neurodegenerative diseases (NDD) is common, with specific changes in walking patterns worsening over time. Ambulatory activity metrics may offer disease-specific progression markers.
Area of Science:
- Neurology
- Gerontology
- Biomedical Engineering
Background:
- Reduced ambulatory activity is a significant burden in neurodegenerative diseases (NDD).
- Objective data on walking behavior patterns and their decline with disease progression in NDDs are limited.
- Understanding these changes is crucial for managing social participation and motor function.
Purpose of the Study:
- To investigate detailed metrics of reduced ambulatory activity in specific NDDs.
- To examine the relationship between ambulatory activity changes and disease duration.
- To test the hypothesis that reduced ambulatory activity is a shared feature across NDDs, with distinct underlying components.
Main Methods:
- A cohort of 65 individuals with NDD (degenerative ataxia, progressive supranuclear palsy, Parkinson's disease) and 38 healthy older adults participated.
- Participants wore a 3-axial accelerometer (activPAL3™) for 7 consecutive days.
- Detailed ambulatory activity metrics were calculated from the accelerometer data.
Main Results:
- All three NDD groups showed significantly decreased average daily walking duration.
- Changes in the number and length of walking bouts and sit-to-stand transfers varied across NDDs.
- Walking duration decline correlated with disease duration, marked by reduced walking bout length and diversity.
Conclusions:
- Reduced ambulatory activity is a common characteristic across different NDDs.
- Specific walking behavior components change with disease duration at varying rates for each NDD.
- Ambulatory activity metrics can serve as ecologically relevant, disease-specific markers for progression and outcomes in NDDs.
Related Concept Videos
Parkinson's Disease: Overview
2.3K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.3K
Alzheimer's Disease: Overview
2.0K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K
Parkinson's Disease: Treatment
1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Neural Regulation
44.5K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
44.5K
Alzheimer's Disease: Treatment
1.2K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K

